Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial
Official title:
Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01510119 -
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01896271 -
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
|
Phase 2 | |
| Recruiting |
NCT06059014 -
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05122546 -
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04904302 -
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT04510597 -
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
|
Phase 3 | |
| Terminated |
NCT02781506 -
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06399419 -
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06361810 -
PSMA Therapy and Immunotherapy in Kidney Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06428708 -
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04370509 -
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
|
Phase 2 | |
| Recruiting |
NCT05012371 -
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
|
Phase 2 | |
| Terminated |
NCT03334409 -
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT02848768 -
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05361720 -
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
|
Phase 2 | |
| Terminated |
NCT03260504 -
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Completed |
NCT02002312 -
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
|
Phase 2 | |
| Recruiting |
NCT04388852 -
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
|
Phase 1 | |
| Recruiting |
NCT05879471 -
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06349642 -
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
|